Palvella Therapeutics (PVLA) Operating Income Growth (1y) (2014 - 2026)
Palvella Therapeutics (PVLA) Operating Income Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 1,386.07% |
| 10 | Palvella Therapeutics | 1.85 Bn | 1.59 Bn | - | -88.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88.73% |
| Dec 31, 2025 | -158.91% |
| Sep 30, 2025 | -101.05% |
| Jun 30, 2025 | -218.09% |
| Mar 31, 2025 | -347.47% |
| Dec 31, 2024 | -132.62% |
| Sep 30, 2024 | 57.13% |
| Jun 30, 2024 | -240.96% |
| Mar 31, 2024 | 88.66% |
| Dec 31, 2023 | 216.21% |
| Sep 30, 2023 | 2.97% |
| Jun 30, 2023 | 116.73% |
| Mar 31, 2023 | -108.01% |
| Dec 31, 2022 | -4.73% |
| Sep 30, 2022 | 36.00% |
| Jun 30, 2022 | 26.44% |
| Mar 31, 2022 | -47.40% |
| Dec 31, 2021 | 11.38% |
| Sep 30, 2021 | -46.26% |
| Jun 30, 2021 | -260.06% |